AlphaCentric Advisors’s Charles River Laboratories CRL Stock Holding History

AlphaCentric Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$272K	Buy	+1,474	New	+$284K	0.27%	93

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

AlphaCentric Advisors's CRL Position: Q4 2024 in Review

AlphaCentric Advisors opened a new position in Charles River Laboratories (CRL) in Q4 2024: 1,474 shares worth $272K. The stake represents 0.27% of the portfolio and ranks #93 among its holdings.

637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

AlphaCentric Advisors held 1,474 shares of Charles River Laboratories worth $272K as of Q4 2024.
Charles River Laboratories was a new AlphaCentric Advisors position in Q4 2024.
Charles River Laboratories made up 0.27% of AlphaCentric Advisors's portfolio in Q4 2024, its #93 holding.
637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.